Nectar lifesciences Limited has successfully completed the extinguishment of 3,00,00,000 equity shares through its tender offer buyback program. The pharmaceutical company announced the completion of this corporate action on January 21, 2026, following the buyback process that concluded earlier this month.

Buyback Program Details

The tender offer buyback was conducted from December 31, 2025, to January 6, 2026, through the stock exchange mechanism. The company repurchased shares at ₹27.00 per equity share, representing a total buyback value of ₹81.00 crores for the 3 crore shares acquired.

Share Capital Reconciliation

The extinguishment process has resulted in a significant reduction in the company's share capital structure. The buyback was executed in compliance with Regulation 24(iv) read with Regulation 11 of the Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018.

Extinguishment Process

All 3,00,00,000 equity shares were extinguished in dematerialized form through National Securities Depository Limited (NSDL). The shares were processed through Master Capital Services Ltd. (DP ID: IN301143) on January 20, 2026. No equity shares were tendered or extinguished in physical form during this buyback program.

The extinguishment was certified by multiple parties including the company's management, secretarial auditor P. Chadha & Associates, and registrar KFin Technologies Limited. NSDL confirmed the debit of 30,000,000 shares from the depository system on January 20, 2026.

Regulatory Compliance

The buyback program was initiated following the public announcement dated December 4, 2025, published on December 5, 2025, along with a corrigendum published on December 10, 2025. The letter of offer was issued on December 29, 2025, providing shareholders with the necessary details for participation in the tender offer.

The entire process was conducted in accordance with SEBI (Buyback of Securities) Regulations, 2018, and SEBI (Depository and Participants) Regulations, 2018. The company has submitted all required documentation and confirmations to both NSE (Symbol: NECLIFE) and BSE (Scrip Code: 532649) as part of its regulatory obligations.

Nectar Lifesciences witnessed a substantial acquisition as Rajasthan Global Securities Private Limited, along with its person acting in concert (PAC) LRSD Securities Private Limited, increased their combined stake in the pharmaceutical company. The acquisition involved the purchase of 3,62,422 equity shares through open market transactions, representing 0.16% of the company's total voting capital.

Acquisition Details

The transaction details reveal a strategic increase in shareholding by the acquirer group. Prior to this acquisition, Rajasthan Global Securities and LRSD Securities collectively held 1,10,07,830 shares, representing 4.91% of Nectar Lifesciences' voting capital.

Regulatory Compliance

The acquisition triggered disclosure requirements under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the combined holding of the acquirer and PAC crossed the 5% threshold.

Company Capital Structure

Nectar Lifesciences maintains a consistent equity share capital structure throughout the transaction period. The company's capital details show:

Acquirer Information

Rajasthan Global Securities Private Limited serves as the primary acquirer, with LRSD Securities Private Limited acting as the person acting in concert. Both entities do not belong to the promoter or promoter group of Nectar Lifesciences. The acquisition was executed through open market purchases, indicating a strategic investment decision by the acquirer group.

The transaction represents a notable development in Nectar Lifesciences' shareholding pattern, with the acquirer group now holding a significant stake above the 5% regulatory threshold. The disclosure ensures transparency and compliance with SEBI regulations governing substantial acquisitions in listed companies.